A clinical trial published in NEJM shows stem cell-based ‘living pharmacy’ treatment may eliminate the need for daily insulin in Type 1 diabetes patients. Most participants achieved insulin independence, though challenges like immune rejection still remain.
The said insulin injections were being sold at substantial discounts of more than 40 percent by the wholesalers and are suspected to be either illegally diverted from the supply chain (or) spurious drugs, thereby raising concerns about their authenticity.
